Stephen Nava

Corporate Officer/Principal at Regulator Affairs Quality Assurance Consulting Services, Inc.

Health Technology

Consumer Services

Stephen Nava active positions

Companies	Position	Start	End
Regulator Affairs Quality Assurance Consulting Services, Inc.	Corporate Officer/Principal	2003-12-31	-

Companies	Position	Start	End
BiPar Sciences, Inc. BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ.	General Counsel	2004-12-31	2011-05-31
Acumen Sciences LLC	General Counsel	2001-12-31	2003-12-31
VIRACTA THERAPEUTICS, INC.	Compliance Officer	2018-07-08	-
VIRACTA THERAPEUTICS, INC.	General Counsel	2018-07-08	-

Texas A&M University-Kingsville

Undergraduate Degree

International

United States

Operational

Sectoral

Health Technology	3
Consumer Services	2

Positions held

Active

Inactive

Listed companies

Private companies

Private companies	4
Sunesis Pharmaceuticals, Inc. Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.	Health Technology
BiPar Sciences, Inc. BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ.	Health Technology
Acumen Sciences LLC
Regulator Affairs Quality Assurance Consulting Services, Inc.